ALNYLAM PHARMACEUTICALS, INC. has recently released its 10-Q report, providing a comprehensive overview of the company's financial and operational performance. Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that focuses on developing therapeutics based on ribonucleic acid interference. The company has a robust pipeline of RNAi therapeutics with six approved products and over 20 clinical programs, targeting a wide range of diseases including hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, hypercholesterolemia, and hemophilia, among others. Additionally, the company has collaborations with leading pharmaceutical and life sciences companies such as Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Novartis AG, and others. Alnylam Pharmaceuticals was founded in 2002 and is headquartered in Cambridge, Massachusetts.
The 10-Q report also includes a detailed discussion of the company's financial condition and results of operations. Alnylam Pharmaceuticals reported an accumulated deficit of $7.41 billion as of June 30, 2025, primarily attributed to costs associated with research and development activities, intellectual property rights, and selling, general, and administrative costs. The company continues to incur significant losses as it focuses on expanding its research platform, drug development programs, and global commercial operations. However, Alnylam Pharmaceuticals aims to achieve financial self-sustainability by the end of 2025 and expects its operating results to fluctuate for the foreseeable future.
The report also highlights the company's research and development strategy, emphasizing its focus on genetically validated genes implicated in the cause or pathway of human disease. Alnylam Pharmaceuticals has six marketed products, including ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, Leqvio, and Qfitlia. Moreover, the company is advancing multiple late-stage investigational programs with a focus on developing transformative medicines to treat prevalent diseases. These programs include zilebesiran for the treatment of hypertension, nucresiran for the treatment of ATTR amyloidosis, and mivelsiran for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
In addition to its commercial and clinical-stage pipeline, Alnylam Pharmaceuticals generates worldwide product revenues from its four commercialized products, primarily in the U.S. and Europe. The company also relies on collaboration revenues from partnerships with Roche, Regeneron, and Novartis. Alnylam Pharmaceuticals expects its sources of potential funding for the next several years to be derived from strategic collaborations, including license and other fees, equity investments, funded research and development, milestone payments, and royalties on product sales by its collaborators.
As a result of these announcements, the company's shares have moved 2.8% on the market, and are now trading at a price of $339.80. For the full picture, make sure to review ALNYLAM PHARMACEUTICALS, INC.'s 10-Q report.
